top of page
Search


Kaiser Reef (ASX: KAU): Henty Gold Mine Acquisition Signals Step-Change in Production Ambitions.
When a junior gold producer strategically adds a proven asset like the Henty Gold Mine to its portfolio, it doesn’t just reshape the company—it often redefines its position in the gold space.

Noel Ong
May 224 min read


OpenLearning (ASX: OLL): Reinventing Education Through AI and Strategic Agility.
In a fast-evolving education sector dominated by digital disruption and shifting learner expectations, OpenLearning Limited (ASX: OLL) continues to chart a bold course through its AI-powered Learning Management System. At the heart of this story is a recent milestone: a debt-to-equity conversion with the Education Centre of Australia (ECA), the company’s largest shareholder, which underscores long-term confidence in OpenLearning’s direction.

Noel Ong
May 214 min read


E79 Gold Mines Unveils New Drill Targets at Laverton South.
In a bold move that underscores its commitment to unlocking value from one of Australia’s most fertile gold provinces, E79 Gold Mines Limited (ASX: E79) has identified several compelling new drill targets at its Laverton South Project. This follows a comprehensive regional review and reinterpretation of large-scale geophysical datasets, inspired partly by the recent Lighthorse discovery by neighbour KalGold (ASX: KAL).

Noel Ong
May 205 min read


Emyria’s Empax Clinics: Scalable Psychedelic Therapy Meets Growing National Demand
Emyria Limited (ASX: EMD) embodies the fusion of compassionate care, groundbreaking science, and a market in dire need of change. Recently, the company has gained attention by uniquely creating a scalable, evidence-based model for psychedelic-assisted therapy within licensed medical settings in Australia.

Noel Ong
May 194 min read


What does a Copper Deposit Discovery Look Like?
A discovery of a copper deposit usually comes with great excitement and is followed by narratives of great wealth generation. Over the recent decades, these type of discoveries are few and the reality for investors is fueled with disappointments and rhetoric of false narratives from the explorers.

Noel Ong
May 1811 min read


Samso News - Weekly Thoughts.
Samso News is all about Making News Simple. Our strategy is now to make the Samso platform a one-stop shop for companies and potential investors to come and find independent and balanced insights on ASX stories.

Noel Ong
May 162 min read


Mapping Australia’s Hidden Copper-Gold Giants: The IOCG Revolution.
In a world where major mineral discoveries are increasingly elusive and hidden beneath cover, Geoscience Australia has crafted a powerful lens into the Earth’s potential—mineral systems-based prospectivity mapping. This approach, backed by decades of data and a deep understanding of geology, is turning Australia into a frontier once again, particularly in the hunt for Iron Oxide Copper-Gold (IOCG) deposits.

Noel Ong
May 165 min read


AI-116: A New Hope in the Fight Against Dementia.
Melbourne-based biotech innovator Algorae Pharmaceuticals (ASX: 1AI) is setting the stage for a game-changing therapeutic breakthrough with its combination drug candidate, AI-116, aimed at treating dementia and neurodegenerative disorders.

Noel Ong
May 164 min read


Heavy Rare Earths Limited (ASX: HRE) Ramps Up Uranium Exploration Across South Australia and Western Australia.
Heavy Rare Earths Limited (ASX: HRE) has released a March 2025 exploration update that signals major progress across its uranium portfolio. With projects in the uranium-rich Curnamona Province of South Australia and the Mid West region of Western Australia, the company is moving aggressively to define targets through passive seismic, airborne surveys, and historical data analysis.

Noel Ong
May 165 min read


Alterity Therapeutics Hits Milestone in Fight Against MSA with Promising Phase 2 Results
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has unveiled compelling Phase 2 clinical trial data for its lead drug candidate, ATH434—a major advancement in treating Multiple System Atrophy (MSA). The findings were presented at the prestigious European MSA Symposium in London, drawing attention from global experts in neurodegenerative research.

Noel Ong
May 165 min read


Actinogen’s Xanamem®: A Promising Leap in Alzheimer’s and Depression Treatment
Actinogen Medical Limited (ASX: ACW) is advancing one of the most promising neuroscience drug candidates in the global biotech pipeline. With its novel oral drug Xanamem® (emestedastat), the company is targeting two of the largest and most urgent unmet needs in modern medicine: Alzheimer’s disease (AD) and Major Depressive Disorder (MDD).

Noel Ong
May 165 min read


Gidji JV Delivers Again: Miramar Strikes More Gold in Kalgoorlie’s Backyard
Gold never sleeps in the Eastern Goldfields—and neither does Miramar Resources (ASX: M2R). The company has just unveiled another suite of promising gold assay results from its 80%-owned Gidji Joint Venture (JV) Project, located just 15km north of Kalgoorlie. These results continue to reinforce the project's potential to host a major new gold camp and come as the Australian dollar gold price surges past A$5,000/oz.

Noel Ong
May 165 min read
bottom of page
